Carmetadin (Trimetazidine)
COMPOSITION
Each film coated tablet contains trimetazidine
(as dihydrochloride) 35 mg.
THERAPEUTIC INDICATIONS
Cardiology:
- continuous care of ischemiac heart-disease: the prevention of stenocardia
attack in monotherapy or in combination with other preparations.
Otolaryngology:
- treatment of cochlear-vestibular disorders of ischemiac origin: dizziness,
buzzing in the ears, hypocausts.
Ophthalmology:
- chorioretinal disorders with ischemiac elements.
CONTRAINDICATIONS
- Hypersensitivity to components of the
preparation;
- Period of lactation.
ADVERSE EFFECTS
The preparation is well tolerated, but sometimes
the rise of insignificant by effects is possible.
From the digestion system: sickness, vomiting.
From the coverlet: itch, nettle rash.
DOSAGE AND ADMINISTRATION
It is recommended to take Carmetadin in 1 tablet
2 times/day (in the morning and in the evening) during a meal, without chewing,
washing down with little water.
The preparation is taken for a long period. The cure duration is established
particularly. The treatment regiment can be revised in 3 months if it is
necessary.
PREGNANCY AND LACTATION
Drug application during pregnancy and lactation
period is possible only if there are any indications and after careful
assessment of benefit/risk ratio.
MANUFACTURED FORM
Film coated tablets with modified release in a
blister. 30 tablets in a blister.
2 blisters in carton box with enclosed leaflet.
|